The anti-CCK effect of glutaramic acid derivatives in anesthetized and conscious rats

T. Takács, István Nagy, A. Pap, Vince Varró

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

The effects of specific gastrin-cholecystokinin (CCK) receptor blockers (proglumide and a new, more potent product of Rotta Research Lab-oratorium, CR-1392) on pancreatic secretion were studied. Proglumide and CR-1392 caused a rightward and parallel shift, respectively, in the dose-response curve of CCK8stimulated pancreatic protein secretion in anesthetized rats, demonstrating a competitive-like mechanism of inhibition. The mean PA2 values, demonstrating the 50% inhibitory dose of proglumide and CR-1392 were 3.7 and 5.7, respectively; i.e., CR-1392 proved to be about 100 times more potent than proglumide. In conscious rats, protein output and the volume of pancreatic juice were significantly decreased for about 2 h in response to 150 mg/kg of proglumide or 3 mg/kg of CR-1392 administered s.c. during diversion of pancreatic juice, demonstrating inhibition of endogenous CCK by glutaramic acid derivatives. Indeed, during reintroduction of precol-lected pancreatic juice into the duodenum, when the release of CCK is known to be almost totally eliminated, pancreatic secretion was not significantly modified by the same doses.

Original languageEnglish
Pages (from-to)465-470
Number of pages6
JournalPancreas.
Volume3
Issue number4
Publication statusPublished - 1988

Fingerprint

Proglumide
Cholecystokinin
Pancreatic Juice
Cholecystokinin B Receptor
Cholecystokinin Receptors
Duodenum
Proteins
glutaramic acid
CR 1392
Research

Keywords

  • CR-1392
  • Pancreatic secretion
  • Proglumide

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism
  • Hepatology
  • Internal Medicine
  • Gastroenterology

Cite this

The anti-CCK effect of glutaramic acid derivatives in anesthetized and conscious rats. / Takács, T.; Nagy, István; Pap, A.; Varró, Vince.

In: Pancreas., Vol. 3, No. 4, 1988, p. 465-470.

Research output: Contribution to journalArticle

Takács, T. ; Nagy, István ; Pap, A. ; Varró, Vince. / The anti-CCK effect of glutaramic acid derivatives in anesthetized and conscious rats. In: Pancreas. 1988 ; Vol. 3, No. 4. pp. 465-470.
@article{507920f4b51b40c58d1cb412daf9ecf7,
title = "The anti-CCK effect of glutaramic acid derivatives in anesthetized and conscious rats",
abstract = "The effects of specific gastrin-cholecystokinin (CCK) receptor blockers (proglumide and a new, more potent product of Rotta Research Lab-oratorium, CR-1392) on pancreatic secretion were studied. Proglumide and CR-1392 caused a rightward and parallel shift, respectively, in the dose-response curve of CCK8stimulated pancreatic protein secretion in anesthetized rats, demonstrating a competitive-like mechanism of inhibition. The mean PA2 values, demonstrating the 50{\%} inhibitory dose of proglumide and CR-1392 were 3.7 and 5.7, respectively; i.e., CR-1392 proved to be about 100 times more potent than proglumide. In conscious rats, protein output and the volume of pancreatic juice were significantly decreased for about 2 h in response to 150 mg/kg of proglumide or 3 mg/kg of CR-1392 administered s.c. during diversion of pancreatic juice, demonstrating inhibition of endogenous CCK by glutaramic acid derivatives. Indeed, during reintroduction of precol-lected pancreatic juice into the duodenum, when the release of CCK is known to be almost totally eliminated, pancreatic secretion was not significantly modified by the same doses.",
keywords = "CR-1392, Pancreatic secretion, Proglumide",
author = "T. Tak{\'a}cs and Istv{\'a}n Nagy and A. Pap and Vince Varr{\'o}",
year = "1988",
language = "English",
volume = "3",
pages = "465--470",
journal = "Pancreas",
issn = "0885-3177",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - The anti-CCK effect of glutaramic acid derivatives in anesthetized and conscious rats

AU - Takács, T.

AU - Nagy, István

AU - Pap, A.

AU - Varró, Vince

PY - 1988

Y1 - 1988

N2 - The effects of specific gastrin-cholecystokinin (CCK) receptor blockers (proglumide and a new, more potent product of Rotta Research Lab-oratorium, CR-1392) on pancreatic secretion were studied. Proglumide and CR-1392 caused a rightward and parallel shift, respectively, in the dose-response curve of CCK8stimulated pancreatic protein secretion in anesthetized rats, demonstrating a competitive-like mechanism of inhibition. The mean PA2 values, demonstrating the 50% inhibitory dose of proglumide and CR-1392 were 3.7 and 5.7, respectively; i.e., CR-1392 proved to be about 100 times more potent than proglumide. In conscious rats, protein output and the volume of pancreatic juice were significantly decreased for about 2 h in response to 150 mg/kg of proglumide or 3 mg/kg of CR-1392 administered s.c. during diversion of pancreatic juice, demonstrating inhibition of endogenous CCK by glutaramic acid derivatives. Indeed, during reintroduction of precol-lected pancreatic juice into the duodenum, when the release of CCK is known to be almost totally eliminated, pancreatic secretion was not significantly modified by the same doses.

AB - The effects of specific gastrin-cholecystokinin (CCK) receptor blockers (proglumide and a new, more potent product of Rotta Research Lab-oratorium, CR-1392) on pancreatic secretion were studied. Proglumide and CR-1392 caused a rightward and parallel shift, respectively, in the dose-response curve of CCK8stimulated pancreatic protein secretion in anesthetized rats, demonstrating a competitive-like mechanism of inhibition. The mean PA2 values, demonstrating the 50% inhibitory dose of proglumide and CR-1392 were 3.7 and 5.7, respectively; i.e., CR-1392 proved to be about 100 times more potent than proglumide. In conscious rats, protein output and the volume of pancreatic juice were significantly decreased for about 2 h in response to 150 mg/kg of proglumide or 3 mg/kg of CR-1392 administered s.c. during diversion of pancreatic juice, demonstrating inhibition of endogenous CCK by glutaramic acid derivatives. Indeed, during reintroduction of precol-lected pancreatic juice into the duodenum, when the release of CCK is known to be almost totally eliminated, pancreatic secretion was not significantly modified by the same doses.

KW - CR-1392

KW - Pancreatic secretion

KW - Proglumide

UR - http://www.scopus.com/inward/record.url?scp=0024210138&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024210138&partnerID=8YFLogxK

M3 - Article

C2 - 3174609

AN - SCOPUS:0024210138

VL - 3

SP - 465

EP - 470

JO - Pancreas

JF - Pancreas

SN - 0885-3177

IS - 4

ER -